We Offer Worldwide Shipping
Login Wishlist

2-Benzoylacetanilide

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1097

  • Specification : 98%(HPLC)

  • CAS number : 959-66-0

  • Formula : C15H13NO2

  • Molecular Weight : 239.27

  • PUBCHEM ID : 70398

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1097

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

239.27

Appearance

Botanical Source

Structure Type

Category

SMILES

C1=CC=C(C=C1)C(=O)CC(=O)NC2=CC=CC=C2

Synonyms

3-oxo-N,3-diphenylpropanamide

IUPAC Name

3-oxo-N,3-diphenylpropanamide

Density

1.205g/cm3

Solubility

Flash Point

194.5ºC

Boiling Point

473.6ºC at 760mmHg

Melting Point

106-108 °C(lit.)

InChl

InChl Key

XRZDIHADHZSFBB-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:959-66-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31884472

Abstract

Background:
T3D-959 is a chemically unique, brain penetrant, dual PPAR delta/gamma agonist with 15-fold higher PPAR delta selectivity. Ubiquitous brain expression of PPAR delta, its critical role in regulating glucose and lipid metabolism, and the Alzheimer’s disease (AD)-like phenotype of PPAR delta null mice motivated this study.

Objective:
To determine safety and tolerability of multiple doses of T3D-959 in subjects with mild to moderate AD, examine systemic and central drug pharmacology and in an exploratory manner, perform cognitive assessments.

Methods:
Thirty-four subjects with mild-to-moderate AD were orally administered 3, 10, 30, or 90 mg of T3D-959 daily for 14 days. There was no inclusion of a placebo arm. Safety and tolerability were monitored. Systemic drug pharmacology was examined via plasma metabolomics LC-MS-MS analysis, cerebral drug pharmacology via FDG-PET measures of changes in Relative CMRgl (R CMRgl, AD-effected regions relative to brain reference regions), and cognitive function assessed before and after drug treatment and again one week after completion of drug treatment, by ADAS-cog11 and the Digit Symbol Substitution Test (DSST).

Results:
T3D-959 was in general safe and well tolerated. Single point pharmacokinetics at the Tmax showed dose dependent exposure. Plasma metabolome profile changes showed dose-dependent systemic effects on lipid metabolism and metabolism related to insulin sensitization. Relative FDG-PET imaging demonstrated dose-dependent, regional, effects of T3D-959 on R CMRgl based on the use of multiple reference regions. ADAS-cog11 and DSST cognitive assessments showed improvements with possible ApoE genotype association and pharmacodynamics related to the mechanism of drug action.

Conclusions:
Exploratory data from this Phase IIa clinical trial supports further clinical investigation of T3D-959 in a larger placebo-controlled clinical study.

KEYWORDS

Alzheimer’s disease, clinical trials, FDG-PET, metabolism, metabolomics, PPAR

Title

An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer’s Disease

Author

Stanley Chamberlain, Hoda Gabriel, Warren Strittmatter, and John Didsbury*

Publish date

2020;

PMID

4393268

Abstract

Antibodies of sufficient homogeneity for sequence studies were readily obtained in high concentrations from rabbits immunized with pneumococcal vaccines. By taking advantage of slightly differing immunologic specificity for Type III and Type VIII capsular polysaccharides, an antibody with unique electrophoretic mobility could be isolated from serum containing several distinct antibody components by using appropriate cross-reacting immunoadsorbents. A unique sequence for the N-terminal 11 amino acid residues of the light chain of the antibody was found, in contrast to several sequences in the antibody mixture from which this component was isolated. The sequence of a nonimmune light chain pool demonstrates even greater heterogeneity. Chymotryptic peptide maps of the antibody light chain show two unique cysteine-containing variable region peptides not seen in maps of nonimmune light chain pool of the same allotypic specificity as that of the antibody light chain. The experimental approach described here may provide further insight into the structure-function relationship of several homogeneous antibodies of closely related specificity for the same polysaccharide antigen.

Title

Isolation and Characterization of Structurally Homogeneous Antibodies from Antipneumococcal Sera

Author

Jean-Claude Jaton, Michael D. Waterfield, Michael N. Margolies, Edgar Haber

Publish date

1970 Jul;

PMID

788531

Abstract

The results of an evaluation of a predischarge utilization review program [PDUR] for Medicaid Patients are presented. A group of hospitals in Allegheny County, Pennsylvania, participated in this program on a voluntary basis prior to the program’s being mandated statewide. All other hospitals in the county experienced retrospective review of Medicaid cases. Our analysis incorporates both types of hospitals in a quasi-experimental design. We found that during the period studied the length of stay of Medicaid patients fell proportionately more than that of the Blue Cross patients in both groups of hospitals; the relative decrease in the length of stay began to occur prior to the introduction of the PDUR program, but no differential effect of the PDUR review process could be demonstrated. The decline in the length of stay was, however, more continuous and smooth in those hospitals participating in the program.

Title

An evaluation of a hospital stay regulatory mechanism.

Author

J R Lave, S Leinhardt

Publish date

1976 Oct;


Description :

Empty ...